Game-Changing Cancer Treatment: Exsure Raises Rs 3 Crore
--Must See--

Game-Changing Cancer Treatment: Exsure Raises Rs 3 Crore to Revolutionize Chemotherapy

What if cancer treatments could be life-saving without the devastating side effects? 

Bhubaneswar-based biotech startup Exsure is on a mission to make that a reality with this Game-Changing Cancer Treatment.

Backed by Unicorn India Ventures with a fresh infusion of Rs 3 crore, Exsure is taking the biotech world by storm with its patented exosomal drug delivery technology, a breakthrough technology that targets cancer and cancer stem cells while minimizing chemotherapy toxicity. 

This could change the lives of cancer patients. Come, let’s discover how this innovative startup is rewriting the rules of cancer care and gearing up for global domination!

The Vision Behind Exsure

Exsure was founded in 2021 by Swastika Paul and Abhishek Dutta. The organization has set out to address one of the most pressing challenges in oncology: the toxic side effects of chemotherapy drugs. 

The traditional cancer treatments often come with huge side effects, and one of the major side effects is that it harms the healthy cells, which leads to severe complications and, in some cases, even has fatal outcomes. 

“During our PhD journey, we witnessed how the toxicity of chemotherapy drugs led to tragic

results. Around 13% of patients undergoing chemotherapy die due to drug toxicity,” shared Swastika Paul, CSO and Co-founder of Exsure. She also mentioned that, their mission is to reduce these toxic effects and improve the quality of life for millions of cancer patients globally.

Exosomal drug delivery platform, the breakthrough innovation of Exsure, is designed to specifically attack cancer cells and cancer stem cells. This will help in minimizing damage to healthy tissues and also reduce the risk of cancer relapse. 

How the Funds Will Be Used

Exsure just received a 3 crore funding from Unicorn India Ventures in the seed round, and this funding will considerably help Exsure to achieve newer milestones:

  • Advancing Non-Clinical Studies: The startup will use the funds to complete critical milestones in its ongoing non-clinical studies, which are being conducted in collaboration with a contract research organization (CRO).
  • Expanding Globally: Exsure plans to strengthen its international presence by marketing its in-house R&D products, including: 
    • Exosure: A 3-in-1 exosome isolation reagent.
    • Leucosure: A reagent for PBMC isolation.
    • PlantExosure: India’s first plant exosome isolation reagent.
    • Dr. Berries: A line of dietary supplements designed for better health.

The organization also intends to grow its team to enhance their marketing and sales strategies, and present their findings to the Central Drugs Standard Control Organization (CDSCO) for approval.

Exsure’s Impressive Growth Journey

In just a few years, Exsure has demonstrated remarkable progress:

  • The startup recorded a five-fold revenue growth last fiscal year.
  • It is on track to serve over 50 clients this year with its cutting-edge R&D products.
  • It has already achieved one milestone in its preclinical study and is gearing up to complete the non-clinical phase within the next 12 months.
  • Exsure was selected for the prestigious OIST Innovation Accelerator Program in Japan, which will facilitate its global business expansion and clinical trials.

Industry Potential and Expert Backing

The Indian Biotechnology sector is rapidly growing, with projections from the India Brand Equity Foundation (IBEF) estimating its market size to reach $150 billion by 2025 and $270-300 billion by 2030. This exponential growth of the biotech industry underscores the wide range of opportunities for biotech startups like Exsure.

Bhaskar Majumdar, Managing Partner at Unicorn India Ventures, expressed confidence in Exsure’s vision. “The fear of Big C is real—not just for patients but also for their families. Exsure’s groundbreaking exosomal drug delivery platform has the potential to transform cancer treatment as we know it. This funding will accelerate their efforts to deploy life-saving solutions globally,” he said.

Exsure has an ambitious roadmap for the next 12 months, which includes:

In this upcoming year, Exsure is focusing on finishing its non-clinical studies and preparing to showcase the data for regulatory approval, marketing a significant step towards bringing its innovative solutions to the market. Along with that, the organization is on a journey to strengthen its team to improve its product development and accelerate its commercialization process. With clear intentions to establish itself as a leader in the biotech domain, Exsure is also trying to expand its global reach with the aim of making its cutting-edge products accessible to clients and markets all across the globe.

With its focus on innovation, growth, and improving the lives of cancer patients, Exsure is well-positioned to make a lasting impact on the biotech industry and redefine the future of oncology care.

Diluxi Arya
Diligence + Intelligence + Learned +Understanding +Xenial + Idealistic = DILUXI. Girl with the golden hands, She has worked hard and transformed BioTecNika's Alerts section with Latest Notifications and Articles with most profound insights. When we need a reliable hand at work, All eyes turn to her!